Scilex Holding Company, an innovative firm focused on acquiring, developing, and commercializing non-opioid pain management products, has declared the end of a Paragraph IV patent infringement lawsuit that Takeda Pharmaceuticals U.S.A. Inc. and Takeda Pharmaceuticals Company LTD (collectively, Takeda) had lodged against them. The announcement came after the U.S. Department of Justice and the U.S. Federal Trade Commission’s 45-day review period expired without any objections towards the Settlement Agreement.
This legal tussle had its beginnings in Scilex’s decision to file for a revised label for its FDA-approved liquid colchicine product, Gloperba. This medication, currently used as a preventative treatment for gout, could see its use extended with the new labeling. It was this intention that triggered Takeda’s Paragraph IV patent infringement lawsuit against the Scilex Parties in November 2023.
The final court approval signifies the end of the dispute. The proceedings were brought to a close by U.S. District Court for the District of Delaware when they entered a Consent Judgment on the 3rd of May, 2024. This ruling granted the approval of the Settlement Agreement filed by Scilex and its wholly-owned subsidiary, Scilex Pharmaceuticals Inc. (collectively known as the Scilex Parties).
Central to these proceedings was the successful resolution of the patent issue. As part of the terms of the Settlement Agreement, the Scilex Parties entered into a License Agreement with Takeda. This agreement permits the Scilex Parties, and bodies affiliated with them, to access certain patents that are currently owned by Takeda. However, the specifics of these agreements remain confidential.
This represents a significant victory for Scilex Holding Company, with the potential to broaden the scope of Gloperba’s use beyond its current set parameters. It solidifies the company’s dedication to non-opioid pain management and paves the way for Gloperba to potentially reach a wider population of patients requiring gout prevention.
As Scilex emerges from this patent infringement lawsuit, the company’s intent to label expansion for Gloperba has been validated. The mentioned license agreement further solidifies its position concerning this pharmaceutical product, thereby bolstering its standing in the field of acute and chronic pain management.
Comments